EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Noninfectious uveitis: Management with biologic agents

S R Rathinam, Somanath Anjana

Indian Journal of Ophthalmology · 2026-06 · 74 (6) · 837-844

DOI: 10.4103/ijo.ijo_3239_25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 12.03.2026. Verfasst von S R Rathinam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Uveitis Service, Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Uveitis, Biological Factors, Disease Management, Biological Products. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uveitis is an inflammatory condition involving the iris, ciliary body, and choroid, and it represents a significant cause of vision loss in both children and adults. The primary goals of uveitis management are to control inflammation, prevent recurrences, and minimize structural damage and subsequent visual impairment. Currently, corticosteroids remain the mainstay of therapy for noninfectious uveitis. In patients with sight-threatening disease, immunosuppressive or steroid-sparing agents are commonly employed. However, for individuals who are intolerant of or refractory to corticosteroids and conventional immunosuppressive therapies, biologic agents have emerged as effective alternative treatments. Among these, anti-tumor necrosis factor alpha (TNF-α) agents have demonstrated efficacy in both uveitis and systemic autoimmune disorders. Adalimumab, an anti-TNF-α agent, was the first biologic approved by the U.S. Food and Drug Administration for the treatment of noninfectious uveitis. Prior to initiating biologic therapy, potential safety concerns, including the risk of infections and demyelinating diseases, must be carefully evaluated. Other biologic agents, such as interferons, interleukin inhibitors, and Janus kinase inhibitors, are emerging as promising therapeutic options for noninfectious uveitis. Further studies are required to better establish the long-term safety and efficacy of biologic therapies. This review highlights the role and effectiveness of biologic agents in the management of noninfectious uveitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UveitisBiological FactorsDisease ManagementBiological ProductsHumans

Stichwörter der Autor:innen

AdalimumabJanus kinase inhibitorsRituximabbiologicsnoninfectious uveitis

Substanzen

Biological FactorsBiological Products

Autor:innen und Institutionen

  • Uveitis Service, Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India.

Zitieren

APA

Rathinam, S. R., & Anjana, S. (2026). Noninfectious uveitis: Management with biologic agents. Indian Journal of Ophthalmology, 74(6), 837-844. https://doi.org/10.4103/ijo.ijo_3239_25

Vancouver

Rathinam SR, Anjana S. Noninfectious uveitis: Management with biologic agents. Indian Journal of Ophthalmology. 2026;74(6):837-844. doi:10.4103/ijo.ijo_3239_25

BibTeX
@article{Rathinam2026,
  author = {Rathinam, S R and Anjana, Somanath},
  title = {Noninfectious uveitis: Management with biologic agents},
  journal = {Indian Journal of Ophthalmology},
  year = {2026},
  volume = {74},
  number = {6},
  pages = {837--844},
  doi = {10.4103/ijo.ijo_3239_25}
}
Kostenlos starten →